Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck 2019 Restructuring Program (legacy) by Year
2019 Restructuring Program (legacy) — Recorded in R&D ($M) ($M)
Merck 2019 Restructuring Program (legacy): $1M in FY2023, down 96.7% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2023
1
Period ended Dec 31, 2023
Change on a year earlier
-96.7%
30 in FY2022
History
3 years
Since FY2021
Sources
3
Documents cited below
Where the FY2023 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Restructuring Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 2019 Restructuring Program (legacy) — Recorded in R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 1 | -96.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 30 | +7.1% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 28 | – | Form 10-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck 2019 Restructuring Program (legacy) ($M), annual FY2021–FY2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr-program2019-line-rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.